Humacyte launched an underwritten offering with a 30-day option for 15% more shares to fund Symvess commercialization, a dialysis BLA supplement and pipeline growth. V012 Phase 3 interim results showed ATEV delivered 91 additional catheter-free days versus AV fistula (p=0.00070), prompting a supplemental BLA filing in H2 2026.
Humacyte has commenced an underwritten public offering of common stock, including a 30-day option to sell up to an additional 15% of shares. Net proceeds are earmarked for Symvess commercialization, a planned biologics license application supplement for a hemodialysis indication, pipeline development and general corporate purposes.
In a prespecified interim analysis of the V012 Phase 3 study in female dialysis patients, ATEV achieved an average of 220 catheter-free days versus 129 for autologous AV fistula, a 91-day advantage (p=0.00070). Meeting the primary endpoint has halted enrollment and supports Humacyte’s plan to file a supplemental BLA in the second half of 2026.
